Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Vikrant Shrotriya

Vikrant Shrotriya

Managing Director, Novo Nordisk India

Appears in 1 story

Notable Quotes

"This is a battle of science, not a battle of consumerisation." — Vikrant Shrotriya, March 2026

"The real challenge is not the price, but a limited understanding of obesity as a disease." — Vikrant Shrotriya, March 2026

Stories

Generic semaglutide floods India as patent expires, cutting prices up to 90%

New Capabilities

Leading Novo Nordisk's defense strategy in India's newly competitive market

Only 200,000 of India's roughly 250 million people living with obesity have ever taken a GLP-1 receptor agonist—the class of drugs that includes Novo Nordisk's blockbuster Ozempic and Wegovy. On March 21, the day after Novo's last Indian patent expired, more than 40 companies began selling generic semaglutide at prices as low as 1,290 rupees a month—about $15, compared to $100-175 for the branded versions. It is the largest single-day generic launch in Indian pharmaceutical history.

Updated Mar 21